2.77
-0.04 (-1.42%)
| Penutupan Terdahulu | 2.81 |
| Buka | 2.79 |
| Jumlah Dagangan | 151,748 |
| Purata Dagangan (3B) | 1,949,388 |
| Modal Pasaran | 101,153,200 |
| Harga / Pendapatan (P/E Ke hadapan) | 3.72 |
| Harga / Jualan (P/S) | 2.19 |
| Harga / Buku (P/B) | 0.810 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 14 Aug 2023 - 18 Aug 2023 |
| Margin Operasi (TTM) | -3,350.19% |
| EPS Cair (TTM) | -0.560 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -81.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.92% |
| Nisbah Semasa (MRQ) | 5.83 |
| Aliran Tunai Operasi (OCF TTM) | -27.47 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -15.32 M |
| Pulangan Atas Aset (ROA TTM) | -24.32% |
| Pulangan Atas Ekuiti (ROE TTM) | -43.47% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Menaik |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Menaik | |
| Stok | SCYNEXIS, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.67 |
|
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.89% |
| % Dimiliki oleh Institusi | 29.83% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |